SUMMARY The methods currently in use for the detection and quantitation of complement activation products are slow and time consuming. We describe a method utilising immunofixation after agarose or cellulose acetate membrane electrophoresis which allows large batches of samples to be screened rapidly for the presence of activation products of C3 and factor B. Further, after immunofixation on agarose the conversion product may be quantitated by densitometry. This method gives similar results to those obtained by crossed immunoelectrophoresis. Using both this technique and crossed immunoelectrophoresis we have been able to confirm that C4 activation occurs during electrophoresis in the absence of EDTA and that in the presence of EDTA it is not demonstrable even in patients with active immune complex disease.
Activation of the complement system results in the formation of fragments of various components of complement. Detection of such fragments in plasma or serum by immunochemical techniques has been widely used as an index of the involvement of complement in disease,1 and it has been suggested that their presence correlates with disease activity better than total component concentrations. 2 The components that have been most studied are C3, C4, and factor B (C3 proactivator, glycine rich fl-glycoprotein (GBG)).
The presence of C3 activation products is a sensitive index of activation of the complement system as C3 is involved in both the classical and alternative pathways. Activation of C3 results in the production of two biologically important effector molecules, C3a and C3b. The latter is broken down by a C3b inactivator (C3INA or KAF) to C3c and C3d.3 C4 is similarly converted to C4a and C4b by the proteolytic action of Cls during activation of the classical pathway. 4 Factor B is broken down in the presence of magnesium ions and factor D (C3 proactivator convertase) to glycine rich a-glycoprotein (GAG), a fragment with alpha mobility, and to glycine rich y-glycoprotein, C3 activator (GGG), a fragment with gamma mobility. Activation of factor B may be Received for publication 10 
IDENTIFICATION OF FACTOR B FRAGMENTS
Immunofixation of fresh normal plasma containing 0-01 M EDTA with anti-factor B after electrophoresis on agarose showed a single band of P2 mobility (Fig. 1) . Activation of complement in vitro by either the classical or alternative pathway resulted in the formation of two additional bands; these were also present in samples collected into EDTA from patients with in vivo complement activation (Fig. 1) . The fast component with alpha electrophoretic mobility represents GAG while the slow component with gamma mobility represents GGG, that is, C3 activator. Both components are always produced by factor B activation.
Quantitative estimation of factor B activation products as determined for C3 revealed low concentrations relative to that of native factor B, regardless of the degree of C3 conversion. Factor B activation and C3 activation were invariably present together when this was due to in vitro activation. C3 activation occurred alone in a number of cases of immune complex disease.
IMMUNOFIXATION OF C4
Fresh normal plasma containing EDTA in concentrations above 0-08M showed a single C4 band after electrophoresis and immunofixation on agarose without EDTA in the buffer (Fig. 1) . Serum likewise showed a single band if electrophoresis was carried out in buffer containing EDTA in concentrations greater than 0X008. With decreasing EDTA concentrations in either sample or buffer the C4 band progressively moved to a more anodal position and a cathodal band of C4 activation products appeared (Fig. 3) . These changes represent C4 activation occurring during electrophoresis and were invariably present in the absence of EDTA. If EDTA was present in both sample and buffer lower concentrations were required; an EDTA concentration of 0 002 in the sample and 0-001 M in the buffer was adequate to prevent in vitro C4 activation. Samples in which C3 had been activated in vitro by immune complexes (classical pathway) showed only a single band of C4 if EDTA was added to the sample in concentrations above 0-08 M before electrophoresis (Fig. 1) . Similarly, EDTA samples from 20 patients with low C4 concentrations and immune complex disease showed only a single band of C4. demonstrated C3 activation products using this technique, the method has not been taken up as a means of detecting complement activation. We have found it particularly suitable for screening large numbers of samples for both C3 and factor B activation products (Fig. 4) . Quantitative measurements are easily obtained, and the sensitivity of the method is similar to that of crossed immunoelectrophoresis, but it is quicker to perform and requires less antiserum. In the case of factor B activation immunofixation is superior to crossed immunoelectrophoresis as the GGG fragment is more clearly demonstrated.
We were unable to demonstrate C4 activation products by either immunofixation or crossed immunoelectrophoresis if EDTA was present in adequate concentrations in the sample or electrophoresis buffer. In the absence of EDTA, C4 activation products were always present, the amount varying with the duration and conditions of electrophoresis. It gested that the C3 activation seen by Versey in this condition was an electrophoretic artefact due to the absence of EDTA in the electrophoretic system. They did, however, show that this 'artefact' occurred to a greater extent in patients with rheumatoid arthritis than in normals and suggested that this may have pathological significance.
